Clinical trial / 2004
High-dose nicotinamide did not prevent or delay the onset of type 1 diabetes in at-risk relatives.
In a randomized double-blind placebo-controlled trial across Europe, Canada, and the USA, 552 relatives of individuals with type 1 diabetes received oral modified release nicotinamide (1.2 g/m2) or placebo for 5 years. Over the trial, 159 participants developed diabetes (82 taking nicotinamide and 77 on placebo). The unadjusted hazard ratio was 1.07 (95% CI 0.78-1.45; p=0.69), and the adjusted hazard ratio was 1.01 (95% CI 0.73-1.38; p=0.97). Nicotinamide also did not affect growth in children, first-phase insulin secretion, or rates of serious adverse events.
- Study type
- Randomized double-blind placebo-controlled trial
- Who was studied
- 552 relatives of people with type 1 diabetes with islet cell antibodies and non-diabetic glucose tolerance
- What was measured
- Development of type 1 diabetes defined by WHO criteria
THE PAPER
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Gale EA, Bingley PJ, Emmett CL, Collier T, European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. Lancet, 2004.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.